Piramal Pharma Ltd Share Price – NSE  / BSE

Pharmaceuticals, Small Cap

Piramal Pharma has allotted 21 lakh equity shares under ESOP on 05 June 2026. Consequently, the paid up equity share capital has increased to Rs. 1,331,34,81,300 (consisting of 133,13,48,130 equity shares of face value of Rs. 10/- each).

Piramal Pharma Ltd fell for a fifth straight session today. The stock is quoting at Rs 165.7, down 3.04% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is up around 0.36% on the day, quoting at 23467.1. The Sensex is at 74624.13, up 0.48%.Piramal Pharma Ltd has gained around 3.37% in last one month.Meanwhile, Nifty Pharma index of which Piramal Pharma Ltd is a constituent, has increased around 1.87% in last one month and is currently quoting at 24214.25, down 1.23% on the day. The volume in the stock stood at 15.47 lakh shares today, compared to the daily average of 61.33 lakh shares in last one month.

The PE of the stock is 29.36 based on TTM earnings ending March 26.

Powered by Capital Market - Live News

In a regulatory filing made on Sunday, the company stated that the US FDA had conducted a good manufacturing practices (GMP) inspection of Piramal Pharma?s facility at Sellersville, USA, from 4th May 2026 to 8th May 2026.

At the conclusion of the inspection, US FDA issued a Form-483, with three observations.

At the closing meeting observations were recommended to be classified under VAI (voluntary action indicated) by inspectors. None of the observation relate to data integrity.

The company is preparing a detailed response to the observations, which will be submitted to the US FDA within the stipulated timelines, Piramal Pharma said in a statement.

Piramal Pharma offers a portfolio of differentiated products and services through its 17 global development and manufacturing facilities and a global distribution network in over 100 countries.

The company a consolidated net loss of Rs 8.83 crore in the quarter ended March 2026 as against net profit of Rs 153.50 crore during the previous quarter ended March 2025. Sales declined 0.08% to Rs 2,751.77 crore in Q4 FY26 as compared with Q4 FY25.

The scrip shed 0.72% to currently trade at Rs 178.45 on the BSE.

Powered by Capital Market - Live News

Net loss of Piramal Pharma reported to Rs 8.83 crore in the quarter ended March 2026 as against net profit of Rs 153.50 crore during the previous quarter ended March 2025. Sales declined 0.08% to Rs 2751.77 crore in the quarter ended March 2026 as against Rs 2754.07 crore during the previous quarter ended March 2025.

For the full year,net loss reported to Rs 325.94 crore in the year ended March 2026 as against net profit of Rs 91.13 crore during the previous year ended March 2025. Sales declined 3.08% to Rs 8869.08 crore in the year ended March 2026 as against Rs 9151.18 crore during the previous year ended March 2025.

Powered by Capital Market - Live News